OncoZenge AB has announced the submission of the Clinical Trial Application for its pivotal Phase III study of BupiZenge™ (BZ003) — a non-opioid treatment candidate targeting oral mucositis–related pain in cancer patients.
As the Contract Research Organization (CRO) supporting this program, LINK Medical is proud to contribute our expertise in site identification, feasibility, preparation of clinical documentation, and CTA submission — further enabling progress toward initiating patient recruitment across multiple European sites in Q2 2026.
We congratulate the OncoZenge team on this important submission and look forward to continued collaboration as the BZ003 trial progresses.
“It is very motivating to now have execution plans in place and submitted to the authorities, with line of sight to patients in Europe. We thank our CRO LINK Medical for their efforts in site selection, documentation and CTA submission, and look forward to regulatory approval and a good collaboration with our study sites next year.”
OncoZenge AB has announced the submission of the Clinical Trial Application for its pivotal Phase III study of BupiZenge™ (BZ003) — a non-opioid treatment candidate targeting oral mucositis–related pain in cancer patients.
As the Contract Research Organization (CRO) supporting this program, LINK Medical is proud to contribute our expertise in site identification, feasibility, preparation of clinical documentation, and CTA submission — further enabling progress toward initiating patient recruitment across multiple European sites in Q2 2026.
We congratulate the OncoZenge team on this important submission and look forward to continued collaboration as the BZ003 trial progresses.
“It is very motivating to now have execution plans in place and submitted to the authorities, with line of sight to patients in Europe. We thank our CRO LINK Medical for their efforts in site selection, documentation and CTA submission, and look forward to regulatory approval and a good collaboration with our study sites next year.”
/Anna Asplind, Phase III Program Manager
🔗 Read the full press release